Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expectant management versus misoprostol for first-trimester retained products of conception
ACTRN12624001463561Phase 4Recruiting
- Sponsor
- Nepean Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of misoprostol in retained placenta (2 arms), sponsored by Nepean Hospital. Primary endpoint: Success rates of expectant versus medical management for first-trimester retained products of conception. Started Feb 2025; status: recruiting.
02
Drugs
misoprostol
03
Conditions
retained placenta
Beyond the preview
Go deeper on ACTRN12624001463561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001463561.